Randomized Trialhigh evidence
Preventive percutaneous coronary intervention versus optimal medical therapy alone for the treatment of vulnerable atherosclerotic coronary plaques (PREVENT): a multicentre, open-label, randomised controlled trial.
Lancet (London, England)·May 4, 2024·PMID 38604213
Why it mattersThis is the first large RCT to demonstrate that focal PCI of non-flow-limiting vulnerable plaques can reduce major adverse cardiac events, challenging the current paradigm of reserving PCI for flow-limiting stenoses. It introduces a potential new indication for intracoronary imaging-guided preventive intervention.
The papers that matter, first.
MedLit ranks the medical literature into a specialty feed with concise summaries, evidence-aware triage, and visual takeaways.
§
MedLit · Evidence, Distilled